[{"id":"d61ddbc3-bb32-4dda-8c4c-406b6f74dc87","acronym":"HARMONIC","url":"https://clinicaltrials.gov/study/NCT05456256","created_at":"2022-07-13T12:56:31.097Z","updated_at":"2024-07-02T16:35:03.235Z","phase":"Phase 2","brief_title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT05456256 - HARMONIC","lead_sponsor":"Lantern Pharma Inc.","biomarkers":" EGFR • ALK • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Pemfexy (pemetrexed) • Tavocept (dimesna)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-05-16"}]